Aroa’s Myriad shows success in lower limb reconstruction Study highlights Myriad’s efficacy and cost-saving benefits Myriad’s potential for $225m market validated by clinical results Special ...

New Zealand-based soft-tissue regeneration company Aroa Biosurgery has hit a key milestone with seven million of its products ...

Aroa Biosurgery expects its Myriad portfolio to continue driving strong growth in the soft tissue reconstruction market Initially focus on trauma segment of market, which based on its estimates ...

Aroa’s first Myriad product, Myriad Matrix – an extracellular matrix graft, indicated for use in soft tissue reconstruction and complex wounds – received FDA clearance in 2019. Since then ...